New analysis finds that the GLP-1 class of medicine — glucagon-like peptide receptor agonists — is more practical in mitigating the danger of 10 obesity-associated cancers than its kind 2 diabetes drug options.
The retrospective research, printed Friday in JAMA Community Open, measured outcomes for a cohort of greater than 1.6 million sufferers with kind 2 diabetes from 2005 to 2018 who have been prescribed GLP-1s, insulin, or metformin. The researchers used information from the primary time level, the prescription of any of the medication, till as much as 15 years after.
Rong Xu, a professor of biomedical informatics at Case Western Reserve College and research writer, mentioned the recognized efficacy of GLP-1 medication in treating weight reduction and managing kind 2 diabetes prompted researchers to do the research.
Get limitless entry to award-winning journalism and unique occasions.
